Metabolic diseases such as obesity and type 2 diabetes are recognized as independent risk factors for hepatocellular carcinoma (HCC). Hyperinsulinemia, a hallmark of these pathologies, is suspected to be involved in HCC development. The molecular adapter growth factor receptor binding protein 14 (Grb14) is an inhibitor of insulin receptor catalytic activity, highly expressed in the liver. To study its involvement in hepatocyte proliferation, we specifically inhibited its liver expression using a short hairpin RNA strategy in mice. Enhanced insulin signaling upon Grb14 inhibition was accompanied by a transient induction of S-phase entrance by quiescent hepatocytes, indicating that Grb14 is a potent repressor of cell division. The proliferation of Grb14-deficient hepatocytes was cell-autonomous as it was also observed in primary cell cultures. Combined Grb14 down-regulation and insulin signaling blockade using pharmacological approaches as well as genetic mouse models demonstrated that Grb14 inhibition-mediated hepatocyte division involved insulin receptor activation and was mediated by the mechanistic target of rapamycin complex 1-S6K pathway and the transcription factor E2F1. In order to determine a potential dysregulation in GRB14 gene expression in human pathophysiology, a collection of 85 human HCCs was investigated. This revealed a highly significant and frequent decrease in GRB14 expression in hepatic tumors when compared to adjacent nontumoral parenchyma, with 60% of the tumors exhibiting a reduced Grb14 mRNA level. Conclusion: Our study establishes Grb14 as a physiological repressor of insulin mitogenic action in the liver and further supports that dysregulation of insulin signaling is associated with HCC. (HEPATOLOGY 2017;65:1352-1368.
I
nsulin is a unique hormone controlling metabolic homeostasis. Secreted by the pancreatic beta cells in response to increased circulating blood glucose levels, insulin acts on its metabolic target tissues to maintain glucose and lipid metabolic homeostasis. (1) In addition to its metabolic actions, insulin behaves as a growth factor, stimulating cell proliferation in many cell types. However, a direct effect of insulin on cell proliferation is poorly documented in vivo, although its involvement is increasingly suspected in the Abbreviations: Akti, Akt inhibitor VIII; BrdU, bromodeoxyuridine; DKO, double knockout; 4EBP1, 4E-binding protein 1; ERK, extracellular signal-regulated kinase; Grb14, growth factor receptor binding protein 14; Grb14i, Grb14 inhibition; GSEA, gene set enrichment analysis; HCC, hepatocellular carcinoma; iLIRKO, inducible liver IR knockout; IR, insulin receptor; KO, knockout; mTORC1, mechanistic target of rapamycin complex 1; PI3K, phosphatidylinositol 3-kinase; Rb, retinoblastoma; shRNA, short hairpin RNA; USi, unspecific inhibition. development of cancer. (2) Epidemiological studies highlighted that individuals with obesity or type 2 diabetes are at higher risk of developing and dying from multiple cancers, including hepatocellular carcinoma (HCC). Among the factors that are suspected to link obesity, diabetes, and cancer, hyperinsulinemia, which develops secondary to insulin resistance, is a likely candidate. (3, 4) Furthermore, expression of the insulin receptor (IR) is deregulated in several types of human tumors, suggesting that IR signaling is involved in the tumorigenic process. (5, 6) IR exists as two splicing isoforms: IR-B, which is mainly expressed in tissues involved in the metabolic effects of insulin, and IR-A, which is expressed in fetal cells and in many tumor cells and is considered to be more mitogenic than IR-B.
(7) Interestingly, we recently showed an overexpression of IR-A to the detriment of IR-B in human HCC, suggesting that IR can be directly implicated in liver neoplastic transformation and/or tumor growth and progression. (6) Insulin stimulation of the IR activates two main intracellular signaling pathways, the phosphatidylinositol 3-kinase (PI3K)-Akt and the Ras-extracellular signal-regulated kinases 1/2 (ERK1/2) pathways. Metabolic actions of insulin are predominantly mediated by the PI3K-Akt signaling cascade, and the mitogenic effect is classically considered to be triggered by the Ras-ERK1/2 pathway. (8, 9) However, depending on the cell type, the PI3K-Akt and Ras-ERK1/2 signaling pathways are likely to be involved to variable degrees. (10, 11) While the molecular pathways mediating insulin-induced metabolic actions are well characterized, the mechanisms whereby insulin stimulates mitogenesis and regulates the cell cycle and G 1 /S progression remain to be fully clarified. (12, 13) Insulin signaling and action are also tightly monitored by negative regulators, including the molecular adapter growth factor receptor binding protein 14 (Grb14). (9, 14) We previously reported that Grb14, which is highly expressed in the liver, is an inhibitor of IR catalytic activity and that its downregulation improves IR signaling and hepatic glucose production in cultured hepatocytes. (15) (16) (17) (18) However, Grb14 deletion also enhances insulin-induced cell growth in mouse embryonic fibroblasts, suggesting that both mitogenic and metabolic effects of insulin are controlled by Grb14 expression level. (19) In this study we demonstrate that Grb14 expression is required to protect hepatocytes against an insulindependent mitogenic signal. We reveal that downstream the IR-B hepatocyte proliferation is driven by Akt-mechanistic target of rapamycin complex 1 (mTORC1) signaling and the retinoblastoma (Rb)-E2F1 pathway. Furthermore, we show that GRB14 expression is significantly decreased in human HCC, hence providing a molecular link to support a role for insulin signaling in the development of HCC.
Materials and Methods

ANIMALS AND TREATMENTS
environment for 1 week before study. The inducible liver IR knockout (iLIRKO) mice have been described. (20) Fifteen-week-old male mice were studied 3 weeks after IR deletion. Generation of S6K1 -/-/ S6K2 -/-mice (S6K DKO) has been described. (21) E2F1 knockout (KO) mice were from Jackson Laboratories. All mice were housed in colony cages with a 12-hour light/dark cycle in a temperature-controlled environment and had free access to water and a regular diet (65% carbohydrate, 11% fat, and 24% protein). All procedures were carried out according to the French guidelines for the care and use of experimental animals and were approved by the Direction d epartementale des services v et erinaires de Paris. Mice were anesthetized with isoflurane before the injection through the penis vein with 2.10 9 pfu of recombinant adenovirus expressing either a control short hairpin RNA (shRNA; unspecific inhibition [USi]) or an shRNA targeting Grb14 inhibition (Grb14i) (18) in a final volume of 150 lL sterile physiological serum. For experiments with inhibitors, mice were injected intraperitoneally twice (18 hours and 2 hours) before sacrifice either with Akt inhibitor VIII (Akti, 50 mg/ kg; Sigma-Aldrich) or rapamycin (4.5 mg/kg; Invivogen). Mice were sacrificed 2 days after adenoviral injection, and 2 hours prior to sacrifice they were intraperitoneally injected with 50 mg/kg of bromodeoxyuridine (BrdU; Sigma). Blood was collected, and part of the liver tissue was fixed in 4% neutral buffered formalin for immunohistochemical analysis. The remaining liver tissue was flash-frozen in liquid nitrogen and stored at 2808C until used.
PATIENTS AND LIVER TISSUE SPECIMENS
Eighty-five HCC and paired adjacent nontumor liver tissues were collected from patients undergoing curative liver resection for HCC at the Saint-Antoine Hospital and stored in a tumor biobank (Pathology Department, Saint-Antoine Hospital) in accordance with French laws and regulations (Commission Nationale de l'Informatique et des Libert es no. 1913901 v0). Part of this tissue collection (43 paired tumor/nontumor) was used in our previous study, where it was designated as "collection 2." (6) Clinicopathologic characteristics of the 85 patients are provided in Supporting Table S2 .
Details on experiments in primary hepatocytes, hepatoma cell lines, protein and mRNA analysis, immunohistochemistry, transcriptome preparation, and data analysis are described in the Supporting Information.
Results
LIVER-SPECIFIC DOWN-REGULATION OF Grb14 EXPRESSION INDUCES HEPATOCYTE PROLIFERATION
To experimentally investigate the consequences of an acute depletion of Grb14 on hepatocyte proliferation, we down-regulated Grb14 expression in liver of C57Bl/6 mice using an adenoviral strategy. Mice were injected with either Grb14 adenoviral shRNA (Grb14i) or control RNA (USi), and livers were analyzed after 48 hours. Grb14 liver expression was decreased by 40% and 30% at the mRNA and protein levels, respectively, in Grb14i-treated mice (Fig.  1A,B) . This significantly improved insulin signaling, as shown by the enhanced phosphorylation of ERK1/2 and Akt and of the downstream effectors of the Akt pathway (glycogen synthase kinase 3b, S6K, 4E-binding protein 1 [4EBP1]) ( Fig. 1B; Supporting Fig.  S1A) . A liver transcriptomic analysis was performed, and gene set enrichment analysis (GSEA) showed a robust positive association between genes altered by Grb14 down-regulation and both cell cycle and DNA replication pathways (Fig. 1C) , especially with the Kyoto Encyclopedia of Genes and Genomes cell cycle gene set (Fig. 1D) . Activation of genes involved in cellular proliferation is thus the prominent feature after a decrease in Grb14 liver content.
To validate the transcriptomic data on the proliferation state of liver cells, mice were injected with BrdU 2 hours before the sacrifice. At 48 hours after the Grb14i injection, 33% of the hepatocytes were in the S phase of the cell cycle compared to 2% in control USi animals (Fig. 1E) . In situ BrdU staining was mainly detected in hepatocytes, and very few other cell types were labeled. Accordingly, several cyclins (E [ccne], A [ccna2], and B1 [ccnb1]) which control the progression of the cell cycle and markers of proliferation (proliferating cell nuclear antigen) or mitosis (phospho-histone H3 and Ki67) were strikingly increased at the mRNA level and/or the protein level after Grb14 down-regulation (Fig. 1F) . By contrast, cyclin D1 (ccnd1) was only moderately increased (Fig. 1F) . Hepatocyte division induced by Grb14 down-regulation transiently peaked 2 days after adenoviral infection (Supporting Fig. S1B ). From day 4, BrdU labeling was similar in USi and Grb14i mouse livers, while concomitantly Grb14 protein expression continued to decrease from day 2 to day 4 (Supporting Fig. S1B,C) . Apoptosis was not modified by Grb14i treatment as assessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) (Supporting Fig.  S1D ), and this short-term inhibition of Grb14 expression did not induce liver toxicity as shown by alanine aminotransferase and aspartate aminotransferase circulating concentrations (Supporting Fig. S1E ).
The effect of Grb14i on hepatocyte proliferation was further investigated in vitro in primary mouse hepatocytes. Hepatocytes isolated from C57Bl/6 mice were treated with USi or Grb14i together with a mitogenic cocktail including insulin that induced one cell division and progression through S phase 48 hours after plating. (22) After Grb14i infection, Grb14 protein expression was inhibited by about 30% after 24 hours of culture and by >90% from 36 hours and until the end of the experiment at 60 hours (Fig. 2B ). Ki67 expression was significantly enhanced in Grb14i-treated compared to USi-treated cells from 24 to 48 hours, indicating that the mitogenic signal was strengthened in the absence of Grb14 ( Fig. 2A) . Similarly, the expression of cyclin E (ccne), cyclin A (ccna2), and cyclin B1 (ccnb1) was significantly enhanced by Grb14 down-regulation, throughout the length of the experiment (Fig. 2B,C) . By contrast, cyclin D1 (ccnd1) mRNA levels were not altered by Grb14i treatment.
Altogether these results reveal that Grb14 acts as a potent inhibitor of hepatocyte division, acting in a cell-autonomous manner probably at the G 1 /S transition.
HEPATOCYTE PROLIFERATION INDUCED BY Grb14 DOWN-REGULATION REQUIRES ITS MOLECULAR PARTNER, THE IR
In liver, IR-B is the major isoform expressed, in agreement with the metabolic function of insulin in this organ (Supporting Fig. S2 ). Upon Grb14 downregulation IR-B expression was slightly decreased by 20%, while IR-A expression was not induced. IR-B thus remained the major isoform expressed in Grb14i liver (Supporting Fig. S2 ). To investigate whether the proliferative effect observed after liver Grb14 inhibition was attributable to IR activation or to other Grb14 partners, we used an iLIRKO mouse line (20) (Fig. 3A) . Basal mRNA and protein Grb14 levels were lower in iLIRKO livers compared to control, according to the reported stimulatory effect of insulin on Grb14 expression (23) (Fig. 3B ). The increase in BrdU incorporation in hepatocyte nuclei observed in control IR lox/lox mice injected with Grb14i was markedly decreased by deletion of the IR (Fig. 3C ). Phosphorylation of ERK1/2, Akt, and S6K was strikingly reduced in liver from iLIRKO mice treated with USi or with Grb14i. This provides evidence that insulin signaling pathways were severely blunted by IR knockout and were not activated by Grb14i treatment, while phosphorylated 4EBP1 was still detected in iLIRKO mice and increased after Grb14 down-regulation (Fig. 3D ). The effect of Grb14 down-regulation on Ki67 expression and on the expression of cyclin E (ccne1), cyclin A (ccna2), and cyclin B1 (ccnb1) was inhibited in liver from iLIRKO compared to IR lox/lox mice ( Fig. 3D ,E). These data indicate that hepatocyte proliferation induced by Grb14 down-regulation was at least partly attributable to activation of IR signaling, suggesting that insulin can act as a powerful mitogen in the liver.
FIG. 1.
Liver-specific inhibition of Grb14 improves insulin signaling and induces hepatocyte proliferation in mice. C57Bl/6J mice were intravenously injected with adenovirus expressing unspecific (USi) or Grb14 (Grb14i) shRNA, and livers were harvested after 2 days. (A) Quantitative RT-PCR analysis of Grb14 expression (left) and quantification of Grb14 protein expression (right). (B) Western blot analysis of Grb14 expression and intracellular signaling pathways in liver lysates from USi and Grb14i mice. (C) GSEA (48) was performed with trancriptomic data from C57Bl/6 mice injected with USi (n 5 3) or Grb14i (n 5 3) (Gene Expression Omnibus GSE81387) and with BioCarta and Kyoto Encyclopedia of Genes and Genomes gene sets. All results are shown in Supporting Table  S1 , and here only the best enrichments are shown (false discovery rate q value < 0.001). (D) GSEA plot for the top enriched pathway showing a significant enrichment for genes up-regulated in liver from Grb14i mice with the Kyoto Encyclopedia of Genes and Genomes list of cell cycle genes. (E) BrdU immunohistochemistry of liver sections (320) and quantification of BrdU-positive cells. (F) Western blot (left) and quantitative RT-PCR (right) analyses of cell cycle markers. Western blots in (B) and (F) are from the same experiments (with the same glyceraldehyde 3-phosphate dehydrogenase loading control) and are shown in two panels for clarity of presentation. Results are the mean 6 standard error of the mean (n 5 6/group). *P < 0.05, **P < 0.01 for Grb14i compared to USi mice. mRNA levels are expressed relative to 18S. For western blot analysis, three representative samples (from six) are shown and glyceraldehyde 3-phosphate dehydrogenase is used as a loading control. Abbreviations: AU, arbitrary units; FDR, false discovery rate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSK, glycogen synthase kinase; KEGG, Kyoto Encyclopedia of Genes and Genomes; NES, normalized enrichment score; PCNA, proliferating cell nuclear antigen.
HEPATOCYTE DIVISION INDUCED BY Grb14 SILENCING IS MEDIATED BY THE PI3K-AktmTORC1 SIGNALING PATHWAY
To evaluate the contribution of the PI3K-AktmTORC1 pathway in Grb14i-induced hepatocyte division, we first used a pharmacological approach. Inhibition of PI3K by wortmannin, of Akt by Akti, or of mTORC1 by rapamycin significantly reduced the increase in BrdU hepatocyte staining induced by the down-regulation of Grb14 (Fig. 4A and data not shown). In correlation with BrdU labeling, Grb14i-mediated increased expression of cyclin A (ccna2), Results are the mean 6 standard error of the mean of three independent cultures. *P < 0.05, **P < 0.01, ***P < 0.005 for Grb14i compared to USi hepatocytes. mRNA levels are expressed relative to 18S. Abbreviations: AU, arbitrary units; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. Results are the mean 6 standard error of the mean (n 5 8-10/group). *P < 0.05, **P < 0.01, ***P < 0.005 for Grb14i compared to USi mice. Results are the mean 6 standard error of the mean (n 5 5-6/group). *P < 0.05, **P < 0.01, ***P < 0.005 for Grb14i compared to USi mice. # P < 0.05, ## P < 0.01, ### P < 0.005 for inhibitortreated compared to dimethyl sulfoxide-treated Grb14i mice. mRNA levels are expressed relative to 18S. For western blot analysis, representative blots of two samples from 5-6/group are shown and glyceraldehyde 3-phosphate dehydrogenase was used as a loading control. Abbreviations: AU, arbitrary units; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Rapa, rapamycin.
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cyclin B1 (ccnb1), and Ki67 was severely inhibited by Akti and rapamycin, while cyclin E (ccne1) was not significantly altered (Fig. 4B,C) . To further investigate the role of mTORC1, we then used S6K double knockout (DKO) mice, which are deleted for both the S6k1 and S6k2 genes. (21) While as expected S6K expression was totally inhibited in S6K DKO mouse liver, the Akt and 4EBP1 signaling pathways were preserved (Fig. 5C ). S6K gene deletion reduced the induction of BrdU hepatocyte nuclear incorporation Results are the mean 6 standard error of the mean (n 5 3-4/group). *P < 0.05, **P < 0.01, ***P < 0.005 for Grb14i compared to USi mice. # P < 0.05, ## P < 0.01, ### P < 0.005 for S6K DKO compared to wild-type Grb14i mice. mRNA levels are expressed relative to 18S. For western blot analysis, two representative samples from 3-4/group are shown and glyceraldehyde 3-phosphate dehydrogenase was used as a loading control. Abbreviations: AU, arbitrary units; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; WT, wild type.
after Grb14i treatment (Fig. 5A,B) . The increase in Ki67 expression and cyclin A (ccna2) and cyclin B1 (ccnb1) gene and protein expression caused by Grb14 down-regulation was also significantly inhibited in S6K DKO liver, while cyclin E (ccne1) mRNA expression was not modified (Fig. 5C,D) . Altogether, these data suggest that hepatocyte proliferation in Grb14i liver is mediated by the Akt-S6K pathway. 
FUNCTIONAL Rb-E2F1 PATHWAY IS CRUCIAL FOR HEPATOCYTE DIVISION INDUCED BY Grb14 DOWN-REGULATION
The next step was to identify the pathway downstream of mTORC1/S6K which mediates Grb14i-dependent hepatocyte division. We analyzed the expression and phosphorylation status of the Rb protein, a well-characterized transcription corepressor which controls the G 1 restriction point. Unphosphorylated Rb binds to the E2F transcription factors, repressing their activity; but the complex is disrupted after Rb phosphorylation, allowing E2F to induce cyclin gene expression and cell cycle progression. (24) The phosphorylation of Rb on different serine residues was strikingly increased by Grb14i treatment in mouse liver as well as in primary hepatocytes, and Rb protein level was also enhanced (Fig. 6A,B) . The transcriptional activity of E2F factors was investigated using an E2F response element reporter gene in transfected primary hepatocytes. Stimulation of hepatocytes by the mitogenic treatment induced E2F activity, and Grb14 down-regulation further enhanced this activity (Fig.  6C ). GSEA showed a significant enrichment in Grb14i liver for genes up-regulated or down-regulated by the deletion of the three members of the Rb family (Rb triple KO) (25) (Fig. 6D) , supporting activation of the Rb-E2F pathway upon Grb14 down-regulation. Interestingly, the increases in Rb phosphorylation and in E2F1 mRNA and protein expression induced by the down-regulation of Grb14 were reduced by Akti or rapamycin treatment, suggesting that the AktmTORC1 pathway was involved in Rb-E2F1 activation in Grb14i mice (Fig. 6E) . This was further illustrated by the decreased effect of Grb14 downregulation on liver e2f1 expression in iLIRKO mice (Fig. 6F ) and on Rb phosphorylation in S6K DKO mice (Supporting Fig. S3A ). We finally validated these results by investigating the effect of Grb14i in E2F1 KO mice. The induction of hepatocyte proliferation consecutive with Grb14 down-regulation was strongly reduced in E2F1 KO mice, as revealed by BrdU immunolabeling (Fig. 7A,B; Supporting Fig. S3B ). As expected, the down-regulation of Grb14 stimulated phosphorylation of ERK1/2, Akt, and S6K similarly in livers of E2F1 KO and wild-type mice (Fig. 7C) , indicating that the absence of E2F1 expression did not modify upstream insulin signaling. In contrast, the increase in cyclin A and B1 protein expression and in Ki67, ccne, ccna2, and ccnb1 mRNA expression induced by Grb14 down-regulation was inhibited in E2F1 KO mouse liver (Fig. 7C,D) . Altogether, these results strongly suggest that the IR-dependent proliferative effect induced by Grb14 down-regulation is mediated at least in part by the Rb-E2F1 pathway.
In basal conditions, insulin binding to its hepatic IR promotes the regulation of glucose and lipid metabolic homeostasis through activation of the Akt-mTORC1 pathway.
(1) However, these data suggest that release of the endogenous repressive action of Grb14 on the IR stimulates a proliferative insulin signal mediated by Akt-mTORC1 and the Rb-E2F1 complex (Fig. 7E ).
Grb14 EXPRESSION IS DECREASED IN HUMAN HEPATOMA CELL LINES AND HCC
To investigate whether dysregulation of Grb14 expression could be related to human hepatocyte transformation, we first compared GRB14 mRNA levels between freshly isolated hepatocytes and five hepatoma cell lines. Interestingly, GRB14 expression was significantly decreased from 50% to 95% in hepatoma cells compared to normal hepatocytes (Fig. 8A) . In addition, whereas E2F1 was hardly detectable in primary hepatocytes, its expression was strikingly enhanced in all hepatoma cell lines. Interestingly, forced expression of Grb14 in PLC/PRF5, HepG2, or Huh6 cells, which expressed low endogenous levels of the gene, significantly reduced insulin-induced proliferation (Fig. 8B) , arguing that Grb14 opposes insulin proliferative action in hepatoma cells. We then examined GRB14 expression level in a collection of 85 HCCs and paired adjacent nontumoral parenchyma. Sixty percent of tumors exhibited a significantly decreased expression of GRB14 (mean 5 58%, P 5 0.0004), while E2F1 expression was enhanced in 89% of HCCs (mean 5 3160%, P < 0.0001) (Fig. 8C,D) . We also investigated data sets in Oncomine and showed that GRB14 expression was significantly decreased in HCC compared to adjacent parenchyma in Roessler liver and Roessler liver 2 collections, including, respectively, 22 and 225 HCC samples (Supporting Fig. S4 ). Of note, a significant association was observed between low GRB14 expression and poor differentiation state in our HCC collection (Supporting Table S3 ). Furthermore, in accordance with our previous study, (6) IR-A expression and the IR-A/IR-B ratio were significantly increased in this HCC collection (Supporting Fig. S5 ). The decrease in GRB14 and the increase in IR-A expression in HCC are supportive of a potential proliferative role of insulin in these tumors.
Discussion
This work reveals that acute inhibition of Grb14 expression in mouse liver is sufficient to trigger hepatocyte proliferation, an effect mostly dependent on IR expression and downstream signaling. We further report that Grb14i liver mitogenic action is mediated by mTORC1-S6K and involves activation of the E2F1 transcription factor. Our study also demonstrates that GRB14 expression is decreased in 60% of the human HCC specimens tested. The occurrence of GRB14 down-regulation together with IR-A induction in HCC supports an increased mitogenic activity of insulin during HCC development. Overall, this report thus identifies insulin as a potent mitogenic factor on hepatocytes and highlights GRB14 as a gatekeeper of the insulin proliferative signal, dysregulation of which could be involved in the pathogenic development of HCC.
Grb14 down-regulation was sufficient to activate the insulin signaling pathways and set off a surge in cell cycle entry in hepatocytes. The release of this proliferative effect in iLIRKO mice pointed to the IR as a key actor in this phenomenon and revealed an unsuspected insulin mitogenic potency in mouse liver. Interestingly, this effect was likely mediated by the IR-B isoform, the major isoform expressed in the liver, because the expression of IR-A was not increased upon Grb14 inhibition. Moreover, our study clearly identified the mTORC1-S6K pathway as the driver of insulininduced hepatocyte proliferation. Dysregulation of the mTOR signaling pathway is common in multiple cancers and has been associated with both cell growth, through activation of protein and lipid synthesis, and cell proliferation. (26) Downstream of mTORC1 aberrant activation, either S6K or 4EBP1 can mediate cell proliferation and tumorigenesis depending on the cellular context. (27, 28) mTOR and S6K were found activated in 40%-50% of human HCCs, playing a pivotal role in the pathogenesis of HCC and associated with a poor prognosis. (29, 30) Hepatocytes are quiescent cells that can enter into the cell cycle to regenerate the liver mass after partial hepatectomy. It has been shown that S6K plays a special role in this scenario as it is required for cyclin D1 expression and hepatocyte proliferation. (31) In addition, liver regeneration is inhibited by rapamycin through decreased S6K activation without modification of 4EBP1 phosphorylation. (32) In accordance with these studies, our data support a potent proliferative function of the mTORC1-S6K pathway downstream of IR signaling. The transient window where hepatocytes were allowed to cycle (cell division Results are the mean 6 standard error of the mean (n 5 8-13/group). *P < 0.05, **P < 0.01, ***P < 0.005 for Grb14i compared to USi. # P < 0.05, ## P < 0.01, ### P < 0.005 for E2F1 KO compared to wild-type mice. mRNA levels are expressed relative to 18S. For western blot analysis, two representative samples from 8-13/group are shown and glyceraldehyde 3-phosphate dehydrogenase was used as a loading control. (E) Model for the regulation of hepatocyte homeostasis through the control by Grb14 of IR signaling. Left: Grb14 represses IR catalytic activity, contributing to the control of liver metabolic homeostasis. Right: Grb14 inhibition enhances insulin signaling and promotes an mTORC1-Rb/E2F1 proliferative signal. Abbreviations: AU, arbitrary units; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TK, tyrosine kinase; WT, wild type. was triggered at day 2, while Grb14 was only partly inhibited) suggests that powerfull counterregulatory mechanisms were operating to suppress the proliferative signal, as observed in liver regeneration after partial hepatectomy. (33) Insulin is a prominent growth factor, but its molecular targets regulating the cell cycle are still poorly defined. (13) The Rb-E2F1 complex plays a pivotal role in cell cycle progression. Phosphorylation of Rb by cyclin-dependent kinases results in Rb inhibition and in the activation of E2F transcription factors to allow cells to enter S phase. (34) Here we show that hepatocyte proliferation consecutive with the downregulation of Grb14 was mediated by Rb phosphorylation and E2F1 activation in an IR-dependent manner. Many mitogens stimulate cell division by regulating this pathway, but this study indicates E2F1 as a mediator of insulin-induced cell proliferation. Overexpression of liver E2F1 in transgenic mice or inactivation of the Rb protein results in liver dysplasia and hepatocarcinogenesis, indicating that E2F1 can contribute to liver oncogenesis by promoting cell proliferation. (25, 35) Interestingly, E2F1 expression is enhanced in liver from obese, glucose-intolerant humans and in cirrhotic livers and is considered as a potential marker for liver fibrosis and both nonalcoholic steatohepatitis and alcoholic cirrhosis. (36, 37) E2F1 is also overexpressed in human HCC, and its expression correlates with tumor cell apoptosis, as shown in this study and by Palaiologou et al. (38) This apparent paradoxical observation can be explained by the dual function of E2F1, which exerts both oncogenic and tumor-suppressive properties. (34) This dual role was nicely illustrated in transgenic mice overexpressing liver E2F1, E2F1 being proproliferative in early stages and proapoptotic in later stages of liver carcinogenesis. (35) E2F1 therefore arises as an important regulator of liver integrity and the pathophysiological evolution of chronic liver diseases.
Insulin signaling pathways were similarly activated by Grb14 down-regulation or by feeding. The question then arises of the molecular mechanism that triggers cell division when IR signaling is stimulated by release of the repressive action of Grb14 but not after a meal. A first hypothesis is provided by the induction of Grb14 expression under insulin stimulation, as shown here in primary hepatocytes and as reported in adipocytes. (23) The increase in Grb14 generated by this feedback loop can tightly regulate the length of signaling and, consequently, the mitogenic effect of insulin. An alternative is that Grb14 binding partners mediate additional proliferative signals. Interestingly, we recently showed that Grb14 and the ubiquitin ligase Chfr cooperate in a negative feedback loop controlling insulin-induced cell proliferation in Xenopus oocytes. (39) Chfr is a tumor-suppressor gene, whose promoter is hypermethylated in numerous cancers. (40) Of note, Chfr methylation correlates with the progression of HCC and is proposed to play a role in the pathogenesis of this cancer. (41, 42) Grb14 also forms in the liver a constitutive complex with the adapter p62/ sqstm1, which controls the timely transit of cells through mitosis and tumor cell proliferation. (43) (44) (45) Cell cycle progression could then be altered by the release of p62 consecutive with Grb14 silencing. Most studies have focused on the metabolic role of Grb14, and very little information is available on the mitogenic function of Grb14 or Grb14 expression in cancer. (14) GRB14 regulates cell cycle progression in breast cancer cells in an insulin-dependent manner, (46) and high expression of GRB14 is independently a good prognosis factor for breast cancer patients. (47) Our present data support an antiproliferative function of Grb14 downstream of insulin signaling and show that a low level of GRB14 could be a bona fide marker of HCC. However, the molecular mechanisms involved in the decreased GRB14 expression in HCC remain to be clarified.
Among the molecular mechanisms potentially underlying the link between metabolic diseases and the increased risk of cancer, the insulin axis is of particular interest. (2) Metabolic diseases are characterized by insulin resistance and elevated levels of circulating insulin. Of note, in the liver some pathways are resistant to the action of insulin, such as gluconeogenesis, while others remain exquisitely sensitive to the hormone, such as lipogenesis and, possibly, cell proliferation. There is to date no implication of insulin/IR in cellular transformation and tumor initiation, but our study provides evidence that hyperinsulinemia can be instrumental for cell proliferation in liver and offers an attractive molecular explanation for the link between hyperinsulinemia and increased HCC prevalence.
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